FDA lifts clinical hold on Filana’s simufilam epilepsy trial
AI Summary- FDA removed Filana Therapeutics’ clinical hold on its simufilam epilepsy-trial application.
- 52.13% was Filana’s share gain, reaching $1.12 at publication time Tuesday.
- FDA imposed the hold in December 2025 while requesting data and protocol changes.